30.07
2.59%
+0.76
After Hours:
30.07
Supernus Pharmaceuticals Inc stock is currently priced at $30.07, with a 24-hour trading volume of 327.42K.
It has seen a +2.59% increased in the last 24 hours and a -7.42% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $29.57 pivot point. If it approaches the $30.62 resistance level, significant changes may occur.
Previous Close:
$29.31
Open:
$29.46
24h Volume:
327.42K
Market Cap:
$1.65B
Revenue:
$607.52M
Net Income/Loss:
$1.32M
P/E Ratio:
41.19
EPS:
0.73
Net Cash Flow:
$110.53M
1W Performance:
+2.28%
1M Performance:
-7.42%
6M Performance:
+32.35%
1Y Performance:
-18.18%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
1550 East Gude Drive, Rockville, MD
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-23 | Resumed | Jefferies | Buy |
Dec-01-21 | Resumed | Jefferies | Buy |
Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Jun-15-20 | Resumed | Jefferies | Hold |
Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
Nov-07-19 | Downgrade | Stifel | Buy → Hold |
Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
Nov-12-18 | Reiterated | B. Riley FBR | Buy |
Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
Dec-04-17 | Upgrade | Janney | Neutral → Buy |
Nov-08-17 | Upgrade | Stifel | Hold → Buy |
Oct-19-17 | Initiated | FBR & Co. | Buy |
Sep-19-17 | Downgrade | Stifel | Buy → Hold |
Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jul-14-17 | Initiated | Janney | Neutral |
Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
Nov-05-15 | Reiterated | Northland Capital | Outperform |
Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
GlobeNewswire Inc.
Supernus Provides Regulatory Update for SPN-830
GlobeNewswire Inc.
Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
GlobeNewswire Inc.
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Zacks Investment Research
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Supernus Pharmaceuticals Inc (SUPN) Revenue 2024
SUPN reported a revenue (TTM) of $607.52 million for the quarter ending December 31, 2023, a -8.95% decline year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Net Income 2024
SUPN net income (TTM) was $1.32 million for the quarter ending December 31, 2023, a -97.83% decrease year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Cash Flow 2024
SUPN recorded a free cash flow (TTM) of $110.53 million for the quarter ending December 31, 2023, a -5.05% decrease year-over-year.
Supernus Pharmaceuticals Inc (SUPN) Earnings per Share 2024
SUPN earnings per share (TTM) was -$0.0026 for the quarter ending December 31, 2023, a -100.25% decline year-over-year.
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Cap:
|
Volume (24h):